Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

- Adenocarcinoma Never Smoking
  - LUN0112
    - Phase II Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
    - PI: Wakelee
    - NC/TN

- EGFR Exon 20 Insertions
  - LUN0113
    - Phase III TAK-788 First-Line Tx vs Platinum-Based Chemo in NSCLC w/ EGFR Exon 20 Insertion Mutations
    - PI: Neal
    - Sponsor: Takeda

- EGFR Mutant (Not Exon 20)
  - ECOG-ACRIN-EA5182
    - Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment in Metastatic EGFR-Mutant NSCLC
    - PI: Neal
    - Sponsor: ECOG-ACRIN

- Without Actionable Genomic Alterations
  - LUN0125
    - Phase II Sacituzumab Govitecan Combinations in First-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer Without Actionable Genomic Alterations
    - PI: Neal
    - Sponsor: Gilead Sciences, Inc.

KEY

- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold